Skip to search formSkip to main contentSkip to account menu

JAK1 Inhibitor INCB052793

Known as: INCB052793 
An orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1), with potential antineoplastic activity. Upon oral administration, INCB052793… 
National Institutes of Health

Related topics

Related topics

1 relation
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Advanced Hematologic Malignancies
Background: The JAK/STAT pathway plays an important role in cytokine and growth factor signal transduction. Dysregulation of the… 
2017
2017
Anti-Myeloma Effects of the Selective JAK1 Inhibitor INCB052793 Using a Platform Study Utilizing the Lagκ-1A Multiple Myeloma Xenograft Model
Introduction: We have previously shown that severe combined immune deficiency (SCID)mice bearing the human multiple myeloma (MM… 
2017
2017
Anti-Myeloma Effects of the Selective JAK1 Inhibitor INCB052793 in Combination with Active Myeloma Agents In Vitro and In Vivo
Review
2016
Review
2016
Effects of INCB052793, a Selective JAK1 Inhibitor, in Combination with Anti-Myeloma Agents on Human Multiple Myeloma (MM) In Vitro and In Vivo
Introduction: Several studies have demonstrated constitutive activation of the JAK-STAT pathway in MM through dysregulated… 
2016
2016
Abstract 1339: Effects of INCB052793, a selective JAK1 inhibitor, in combination with standard of care agents in human multiple myeloma (MM) cell lines and xenograft models
Several studies have demonstrated constitutive activation of the JAK-STAT pathway in MM through dysregulated signaling of… 
2015
2015
Abstract 779: Blockade of the IL-6/JAK/STAT3 signaling pathway inhibits pancreatic tumor cell growth in 3D spheroid cultures and in xenograft models
Emerging evidence has demonstrated the importance of tumor-associated inflammation in the development and progression of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)